Please login to the form below

Not currently logged in

Bioniche appoints James Rae as chair

He previously led several Canadian biopharma firms as CEO

Bioniche has named James Rae, CEO of Viron Therapeutics, as chair of its board of directors.

He replaces Graeme McRae at the Canadian company, with McRae retaining his position as CEO and president.

"Mr Rae brings a wealth of sector experience to our board of directors," said McRae. "His knowledge and network will serve the company well as we work to complete important R&D projects and grow revenues."

Rae has a rich pedigree in the Canadian biopharma industry serving as CEO at several companies.

Prior to joining Viron in 2007, he was CEO of Cytochroma, chair and CEO of Resolution pharma, and chair and CEO of Vaxis Therapeutics.

Extending back even further, he also served as president and CEO of Cangene, where he was responsible for restructuring and orchestrating a takeover of the company.

He began his pharma career at Searle, where he spent 18 years, including several as CEO.

Bioniche also announced several changes to its senior management structure, with Cameron Groome, executive VP, corporate & strategic development; Jim Phillips, senior VP, industry relations; Dr Dragan Rogan, chief veterinary scientific officer and Dr Gary Weber, president, Bioniche Food Safety (US) all leaving the company.

Michael Rubin has joined Bioniche, however, as VP, business development.

1st August 2012


Featured jobs

Subscribe to our email news alerts


Add my company

WCG is an independent, global agency specialising in healthcare communications. Our value as a company is about being the positive...

Latest intelligence

Revisiting Instagram for pharma
In pharma, Instagram usage is increasing because it offers so many benefits to engage with patients and HCPs...
The one multichannel question you must ask
There is a question every marketer should ask when designing a multichannel communications strategy...
Medius Deal Watch
Deal Watch September 2016
Abbott, Allergan, Celgene, Moderna, Pfizer and Takeda feature in this month's pharma deals round-up...